BR112019005539A2 - métodos de tratamento de lesão renal aguda - Google Patents

métodos de tratamento de lesão renal aguda

Info

Publication number
BR112019005539A2
BR112019005539A2 BR112019005539-8A BR112019005539A BR112019005539A2 BR 112019005539 A2 BR112019005539 A2 BR 112019005539A2 BR 112019005539 A BR112019005539 A BR 112019005539A BR 112019005539 A2 BR112019005539 A2 BR 112019005539A2
Authority
BR
Brazil
Prior art keywords
kidney injury
acute kidney
treatment methods
injury treatment
methods
Prior art date
Application number
BR112019005539-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Lagu Bharat
Patane Michael
Tozzo Effie
Trzaska Scott
Original Assignee
Mitobridge, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge, Inc. filed Critical Mitobridge, Inc.
Publication of BR112019005539A2 publication Critical patent/BR112019005539A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
BR112019005539-8A 2016-10-05 2017-10-05 métodos de tratamento de lesão renal aguda BR112019005539A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404390P 2016-10-05 2016-10-05
US62/404,390 2016-10-05
PCT/US2017/055400 WO2018067857A1 (en) 2016-10-05 2017-10-05 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
BR112019005539A2 true BR112019005539A2 (pt) 2019-06-18

Family

ID=60153507

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005539-8A BR112019005539A2 (pt) 2016-10-05 2017-10-05 métodos de tratamento de lesão renal aguda

Country Status (33)

Country Link
US (1) US20210283116A1 (cg-RX-API-DMAC7.html)
EP (1) EP3522880B1 (cg-RX-API-DMAC7.html)
JP (1) JP7065839B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190062502A (cg-RX-API-DMAC7.html)
CN (1) CN109789117B (cg-RX-API-DMAC7.html)
AU (1) AU2017340760B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005539A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036723A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019004561A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124759T1 (cg-RX-API-DMAC7.html)
DK (1) DK3522880T3 (cg-RX-API-DMAC7.html)
ES (1) ES2859487T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210294T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053557T2 (cg-RX-API-DMAC7.html)
IL (1) IL265749A (cg-RX-API-DMAC7.html)
JO (1) JOP20190056B1 (cg-RX-API-DMAC7.html)
LT (1) LT3522880T (cg-RX-API-DMAC7.html)
MA (1) MA46459B1 (cg-RX-API-DMAC7.html)
MD (1) MD3522880T2 (cg-RX-API-DMAC7.html)
MX (1) MX387518B (cg-RX-API-DMAC7.html)
MY (1) MY192385A (cg-RX-API-DMAC7.html)
PH (1) PH12019500725A1 (cg-RX-API-DMAC7.html)
PL (1) PL3522880T3 (cg-RX-API-DMAC7.html)
PT (1) PT3522880T (cg-RX-API-DMAC7.html)
RS (1) RS61573B1 (cg-RX-API-DMAC7.html)
RU (1) RU2753607C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201901925RA (cg-RX-API-DMAC7.html)
SI (1) SI3522880T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100111T1 (cg-RX-API-DMAC7.html)
TW (1) TWI778982B (cg-RX-API-DMAC7.html)
UA (1) UA124019C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018067857A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201901743B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016333963C1 (en) 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US11358954B2 (en) * 2016-04-13 2022-06-14 Mitobridge, Inc. PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN109843857B (zh) * 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
WO2021013772A1 (en) 2019-07-19 2021-01-28 Vifor (International) Ag Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
CA3212825A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN115813901B (zh) * 2022-10-20 2024-10-22 南京市儿童医院 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539403C (en) 2003-09-19 2013-11-19 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
RU2320341C1 (ru) * 2006-06-13 2008-03-27 Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук Средство для лечения острой обструкции верхних мочевыводящих путей
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
JP2016512201A (ja) 2013-03-08 2016-04-25 アッヴィ・インコーポレイテッド 急性腎障害の治療方法
JP2016520552A (ja) * 2013-04-05 2016-07-14 ソーク インスティテュート フォー バイオロジカル スタディーズ Pparアゴニスト
EP2862574A1 (en) 2013-10-15 2015-04-22 Sanofi {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
CN110007084B (zh) * 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
US20170305894A1 (en) * 2014-10-08 2017-10-26 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
AU2016333963C1 (en) * 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof

Also Published As

Publication number Publication date
AU2017340760A1 (en) 2019-03-21
PL3522880T3 (pl) 2021-08-23
CY1124759T1 (el) 2022-07-22
ES2859487T3 (es) 2021-10-04
RU2019111421A (ru) 2020-11-06
JP2019533660A (ja) 2019-11-21
ZA201901743B (en) 2022-04-28
MA46459B1 (fr) 2021-03-31
MA46459A (fr) 2019-08-14
AU2017340760B2 (en) 2023-07-27
MY192385A (en) 2022-08-18
MX2019003949A (es) 2019-06-10
PT3522880T (pt) 2021-02-22
RS61573B1 (sr) 2021-04-29
SG11201901925RA (en) 2019-04-29
JOP20190056A1 (ar) 2019-03-24
CN109789117A (zh) 2019-05-21
RU2019111421A3 (cg-RX-API-DMAC7.html) 2021-02-05
UA124019C2 (uk) 2021-07-07
EP3522880B1 (en) 2020-12-02
WO2018067857A1 (en) 2018-04-12
TWI778982B (zh) 2022-10-01
MD3522880T2 (ro) 2021-03-31
PH12019500725A1 (en) 2019-08-05
SMT202100111T1 (it) 2021-05-07
LT3522880T (lt) 2021-03-25
DK3522880T3 (en) 2021-01-18
TW201815391A (zh) 2018-05-01
MX387518B (es) 2025-03-18
RU2753607C2 (ru) 2021-08-18
CO2019004561A2 (es) 2019-07-31
KR20190062502A (ko) 2019-06-05
CN109789117B (zh) 2022-08-23
JP7065839B2 (ja) 2022-05-12
SI3522880T1 (sl) 2021-07-30
JOP20190056B1 (ar) 2022-03-15
IL265749A (en) 2019-06-30
HRP20210294T1 (hr) 2021-04-16
HUE053557T2 (hu) 2021-07-28
EP3522880A1 (en) 2019-08-14
CA3036723A1 (en) 2018-04-12
US20210283116A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
EP3720553C0 (en) PHOTOBIOMODULATION DEVICE FOR THE TREATMENT OF A RETINAL DISEASE
EP3442577A4 (en) TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST TRANSLATION MODIFIED ANTI-VEGF FAB
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
MA45192A (fr) Traitement d'association
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
MX369921B (es) Tratamiento de la hgna y ehna.
EA201790737A1 (ru) Комбинированная терапия
PH12019500725A1 (en) Methods of treating acute kidney injury
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
EP3362013C0 (en) ENERGY DEVICE FOR THE TREATMENT OF AN EYE DISORDER
IL258521B1 (en) Combination therapy for the treatment of cancer
EP3565558A4 (en) POLYTHERAPY FOR CANCER TREATMENT
EP3337828C0 (en) PCSK9 inhibitor antibodies for the treatment of hyperlipidemic patients undergoing lipoprotein apheresis
MX2016010173A (es) Metodos de tratamiento de enfermedad de alzheimer.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
EP3720509A4 (en) GENE THERAPY WITH A GLOBIN GENE FOR THE TREATMENT OF HEMOGLOBINOPATHIES
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
EP3852816A4 (en) METHODS OF TREATMENT OF CANCER
EP3458062A4 (en) Treatment of pain
CY1122374T1 (el) Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.